H.C. Wainwright analyst Patrick Trucchio maintained a Buy rating on Vir Biotechnology (NASDAQ:VIR) on Wednesday, setting a price target of $100, which is approximately 140.96% above the present share price of $41.5.
Trucchio expects Vir Biotechnology to post earnings per share (EPS) of -$0.27 for the fourth quarter of 2020.
The current consensus among 7 TipRanks analysts is for a Moderate Buy rating of shares in Vir Biotechnology, with an average price target of $55.
The analysts price targets range from a high of $100 to a low of $24.
In its latest earnings report, released on 06/30/2020, the company reported a quarterly revenue of $66.99 million and a net profit of -$29.05 million. The company's market cap is $5.27 billion.
According to TipRanks.com, H.C. Wainwright analyst Patrick Trucchio is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 2.7% and a 47.37% success rate.
Vir Biotechnology, Inc. engages in the provision of technologies to treat and prevent infectious diseases. Its technology platforms include antibody, T cell, innate immunity, and siRNA. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in 2016 and is headquartered in San Francisco, CA.